Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tony R Reid

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Oxford Medical Case Reports|December 18, 2019
Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patientsMichael Bouvet, Tony R Reid, Chris Larson, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 12, 2021
RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopeniaBryan Oronsky, Pedro Cabrales, Scott Caroen, et al.
Future Oncology (London, England)|July 28, 2023
TGF-β: the apex predator of immune checkpointsBryan Oronsky, Pedro Cabrales, Babak Alizadeh, et al.
Human Gene Therapy|September 8, 2011
Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomographyDaniel Y Sze, Andrei H Iagaru, Sanjiv S Gambhir, et al.
Clinical Reviews in Allergy & Immunology|February 20, 2021
A Review of Persistent Post-COVID Syndrome (PPCS)Bryan Oronsky, Christopher Larson, Terese C Hammond, et al.
Oncotarget|August 18, 2015
Going viral: a review of replication-selective oncolytic adenovirusesChristopher Larson, Bryan Oronsky, Jan Scicinski, et al.
Journal of Cancer Research and Clinical Oncology|April 19, 2017
RRx-001 protects against cisplatin-induced toxicitiesBryan Oronsky, Tony R Reid, Christopher Larson, et al.
Expert Opinion on Therapeutic Targets|April 2, 2020
TGF-beta: a master immune regulatorChristopher Larson, Bryan Oronsky, Corey A Carter, et al.
Case Reports in Oncology|July 13, 2016
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum DoubletsCorey A Carter, Bryan Oronsky, Scott Caroen, et al.
Neoplasia (New York, N.Y.)|December 12, 2017
Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A ReviewBryan Oronsky, Patrick Ma, Tony R Reid, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Oxford Medical Case Reports|December 18, 2019
Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patientsMichael Bouvet, Tony R Reid, Chris Larson, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 12, 2021
RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopeniaBryan Oronsky, Pedro Cabrales, Scott Caroen, et al.
Future Oncology (London, England)|July 28, 2023
TGF-β: the apex predator of immune checkpointsBryan Oronsky, Pedro Cabrales, Babak Alizadeh, et al.
Human Gene Therapy|September 8, 2011
Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomographyDaniel Y Sze, Andrei H Iagaru, Sanjiv S Gambhir, et al.
Clinical Reviews in Allergy & Immunology|February 20, 2021
A Review of Persistent Post-COVID Syndrome (PPCS)Bryan Oronsky, Christopher Larson, Terese C Hammond, et al.
Oncotarget|August 18, 2015
Going viral: a review of replication-selective oncolytic adenovirusesChristopher Larson, Bryan Oronsky, Jan Scicinski, et al.
Journal of Cancer Research and Clinical Oncology|April 19, 2017
RRx-001 protects against cisplatin-induced toxicitiesBryan Oronsky, Tony R Reid, Christopher Larson, et al.
Expert Opinion on Therapeutic Targets|April 2, 2020
TGF-beta: a master immune regulatorChristopher Larson, Bryan Oronsky, Corey A Carter, et al.
Case Reports in Oncology|July 13, 2016
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum DoubletsCorey A Carter, Bryan Oronsky, Scott Caroen, et al.
Neoplasia (New York, N.Y.)|December 12, 2017
Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A ReviewBryan Oronsky, Patrick Ma, Tony R Reid, et al.
Pageof 6